The dual roles of obesity in chronic kidney disease: A review of the current literature

Current Opinion in Nephrology and Hypertension

Volumn 25, Issue 3, 2016, Pages 208-216

  Rhee, Connie M ^a   Ahmadi, Seyed Foad ^a   Kalantar Zadeh, Kamyar ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Excess Fat; Kidney disease; Mortality; Obesity paradox; Reverse epidemiology

Indexed keywords

BODY FAT; BODY MASS; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; GRAFT RECIPIENT; HEMODIALYSIS PATIENT; HUMAN; KIDNEY TRANSPLANTATION; OBESITY; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PERITONEAL DIALYSIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; WEIGHT REDUCTION; ADIPOSE TISSUE; COMPLICATION; DISEASE COURSE; HEMODIALYSIS; METABOLISM; MORTALITY; RENAL INSUFFICIENCY, CHRONIC;

ADIPOSE TISSUE; DISEASE PROGRESSION; HUMANS; OBESITY; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 84961392977     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0000000000000212     Document Type: Review

References (74)

1. Finkelstein EA, Trogdon JG, Cohen JW, Dietz W. Annual medical spending attributable to obesity: payer-and service-specific estimates. Health Aff (Mill wood) 2009; 28:w822-w831.
2. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA 2014; 311:806-814.
3. Guh DP, Zhang W, Bansback N, et al. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health 2009; 9:88.
4. Kalantar-Zadeh K, Block G, Horwich T, Fonarow GC. Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. J Am Coll Cardiol 2004; 43:1439-1444.
5. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003; 63:793-808.
6. Kalantar-Zadeh K, Rhee CM, Amin AN. To legitimize the contentious obesity paradox. Mayo Clin Proc 2014; 89:1033-1035.
7. Park J, Ahmadi S-F, Streja E, et al. Obesity paradox in end-stage kidney disease patients. Prog Cardiovasc Dis 2014; 56:415-425.
8. Sharma A, Vallakati A, Einstein AJ, et al. Relationship of body mass index with total mortality, cardiovascular mortality, and myocardial infarction after coronary revascularization: evidence from a meta-analysis. Mayo Clin Proc 2014; 89:1080-1100.
9. Stenvinkel P, Zoccali C, Ikizler TA. Obesity in CKD: what should nephrologists know? J Am Soc Nephrol 2013; 24:1727-1736.
10. Fox CS, Larson MG, Leip EP, et al. Predictors of new-onset kidney disease in a community-based population. JAMA 2004; 291:844-850.
11. Tsujimoto T, Sairenchi T, Iso H, et al. The dose-response relationship between body mass index and the risk of incident stage >3 chronic kidney disease in a general Japanese population: the Ibaraki prefectural health study (IPHS). J Epidemiol 2014; 24:444-451.
12. Wang Y, Chen X, Song Y, et al. Association between obesity and kidney disease: a systematic review and meta-analysis. Kidney Int 2008; 73:19-33.
13. Kalantar-Zadeh K, Abbott KC, Salahudeen AK, et al. Survival advantages of obesity in dialysis patients. Am J Clin Nutr 2005; 81:543-554.
14. Hsu CY, McCulloch CE, Iribarren C, et al. Body mass index and risk for end-stage renal disease. Ann Inter Med 2006; 144:21-28.
15. Munkhaugen J, Lydersen S, Wideroe TE, Hallan S. Prehypertension, obesity, and risk of kidney disease: 20-year follow-up of the HUNT I study in Norway. Am J Kidney Dis 2009; 54:638-646.
16. Panwar B, Hanks LJ, Tanner RM, et al. Obesity, metabolic health, and the risk of end-stage renal disease. Kidney Int 2015; 87:1216-1222.
17. Pscheidt C, Nagel G, Zitt E, et al. Sex-and time-dependent patterns in risk factors of end-stage renal disease: a large Austrian cohort with up to 20 years of follow-up. PLoS One 2015; 10:e0135052.
18. Vivante A, Golan E, Tzur D, et al. Body mass index in 1.2 million adolescents and risk for end-stage renal disease. Arch Intern Med 2012; 172:1644-1650.
19. Lu JL, Molnar MZ, Naseer A, et al. Association of age and BMI with kidney function and mortality: a cohort study. Lancet Diabetes Endocrinol 2015; 3:704-714.
20. Ahmadi SF, Zahmatkesh G, Ahmadi E, et al. Association of Body Mass Index with Clinical Outcomes in Non-Dialysis-Dependent Chronic Kidney Disease: A Systematic Review and Meta-Analysis. Cardiorenal Med 2016; 6:37-49.
21. Lu JL, Kalantar-Zadeh K, Ma JZ, et al. Association of body mass index with outcomes in patients with CKD. J Am Soc Nephrol 2014; 25:2088-2096.
22. Hou CC, Shyu RS, Lee WJ, et al. Improved renal function 12 months after bariatric surgery. Surg Obes Relat Dis 2013; 9:202-206.
23. Amor A, Jimenez A, Moize V, et al. Weight loss independently predicts urinary albumin excretion normalization in morbidly obese type 2 diabetic patients undergoing bariatric surgery. Surg Endosc 2013; 27:2046-2051.
24. Wanner C, Jager KJ. Kidneys do not like excess body fat. Lancet Diabetes Endocrinol 2015; 3:669-671.
25. Mallamaci F, Tripepi G. Obesity and CKD progression: hard facts on fat CKD patients. Nephrol Dial Transplant 2013; 28(Suppl 4):iv105-iv108.
26. Wickman C, Kramer H. Obesity and kidney disease: potential mechanisms. Semin Nephrol 2013; 33:14-22.
27. Warnke RA, Kempson RL. The nephrotic syndrome in massive obesity: a study by light, immunofluorescence, and electron microscopy. Arch Pathol Lab Med 1978; 102:431-438.
28. Spoto B, Zoccali C. Spleen IL-10, a key player in obesity-driven renal risk. Nephrol Dial Transplant 2013; 28:1061-1064.
29. Stenvinkel P, Ketteler M, Johnson RJ, et al. IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia: the good, the bad, and the ugly. Kidney Int 2005; 67:1216-1233.
30. Wolf G, Ziyadeh FN. Leptin and renal fibrosis. Contrib Nephrol 2006; 151:175-183.
31. Sharma K, Ramachandrarao S, Qiu G, et al. Adiponectin regulates albumi-nuria and podocyte function in mice. J Clin Invest 2008; 118:1645-1656.
32. Rhee CM, Nguyen DV, Moradi H, et al. Association of adiponectin with body composition and mortality in hemodialysis patients. Am J Kidney Dis 2015; 66:313-321.
33. Evans M, Fryzek JP, Elinder CG, et al. The natural history of chronic renal failure: results from an unselected, population-based, inception cohort in Sweden. Am J Kidney Dis 2005; 46:863-870.
34. Kovesdy CP, Anderson JE, Kalantar-Zadeh K. Paradoxical association between body mass index and mortality in men with CKD not yeton dialysis. Am J Kidney Dis 2007; 49:581-591.
35. Dalrymple LS, Katz R, Kestenbaum B, et al. Chronic kidney disease and the risk of end-stage renal disease versus death. J Gen Intern Med 2011; 26:379-385.
36. Madero M, Sarnak MJ, Wang X, et al. Body mass index and mortality in CKD. Am J Kidney Dis 2007; 50:404-411.
37. Weiner DE, Tighiouart H, Elsayed EF, et al. The relationship between non-traditional risk factors and outcomes in individuals with stage 3 to 4 CKD. Am J Kidney Dis 2008; 51:212-223.
38. Degoulet P, Legrain M, Reach I, et al. Mortality risk factors in patients treated by chronic hemodialysis. Report of the Diaphane collaborative study. Nephron 1982; 31:103-110.
39. Leavey SF, Strawderman RL, Jones CA, et al. Simple nutritional indicators as independent predictors of mortality in hemodialysis patients. Am J Kidney Dis 1998; 31:997-1006.
40. Fleischmann E, Teal N, Dudley J, et al. Influenceofexcess weightonmortality and hospital stay in 1346 hemodialysis patients. Kidney Int 1999; 55:1560-1567.
41. Johansen KL, Young B, Kaysen GA, Chertow GM. Association of body size with outcomes among patients beginning dialysis. Am J Clin Nutr 2004; 80:324-332.
42. Kalantar-Zadeh K, Kopple JD, Kilpatrick RD, et al. Association of morbid obesity and weight change over time with cardiovascular survival in hemo-dialysis population. Am J Kidney Dis 2005; 46:489-500.
43. Leavey SF, McCullough K, Hecking E, et al. Body mass index and mortality in 'healthier' as compared with 'sicker' haemodialysis patients: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2001; 16:2386-2394.
44. Port FK, Ashby VB, Dhingra RK, et al. Dialysis dose and body mass index are strongly associated with survival in hemodialysis patients. J Am Soc Nephrol 2002; 13:1061-1066.
45. Doshi M, Streja E, Rhee CM, et al. Examining the robustness of the obesity paradox in maintenance hemodialysis patients: a marginal structural model analysis. Nephrol Dial Transplant 2015; doi: 10.1093/ndt/gfv379. [Epub ahead of print]
46. Stenvinkel P, Gillespie IA, Tunks J, et al. Inflammation modifies the paradoxical association between body mass index and mortality in hemodialysis patients. J Am Soc Nephrol 2015;doi:10.1681/ASN.2015030252. [Epub aheadofprint]
47. Snyder JJ, Foley RN, Gilbertson DT, et al. Body size and outcomes on peritoneal dialysis in the United States. Kidney Int 2003; 64:1838-1844.
48. Abbott KC, Glanton CW, Trespalacios FC, et al. Body mass index, dialysis modality, and survival: analysis of the United States Renal Data System Dialysis Morbidity and Mortality Wave II Study. Kidney Int 2004; 65:597-605.
49. Stack AG, Murthy BV, Molony DA. Survival differences between peritoneal dialysis and hemodialysis among 'large' ESRD patients in the United States. Kidney Int 2004; 65:2398-2408.
50. Ahmadi SF, Zahmatkesh G, Streja E, et al. Association of body mass index with mortality in peritoneal dialysis patients: a systematic review and meta-analysis. Perit Dial Int 2015; doi: 10.3747/pdi.2015.00052. [Epub ahead of print]
51. Chan W, Bosch JA, Jones D, et al. Obesity in kidney transplantation. J Ren Nutr 2014; 24:1-12.
52. Molnar MZ, Streja E, Kovesdy CP, et al. Associations of body mass index and weight loss with mortality in transplant-waitlisted maintenance hemodialysis patients. Am J Transplant 2011; 11:725-736.
53. Cannon RM, Jones CM, Hughes MG, et al. The impact of recipient obesity on outcomes after renal transplantation. Ann Surg 2013; 257:978-984.
54. Hatamizadeh P, Molnar MZ, Streja E, et al. Recipient-related predictors of kidney transplantation outcomes in the elderly. Clin Transplant 2013; 27:436-443.
55. Ahmadi SF, Zahmatkesh G, Streja E, et al. Body mass index and mortality in kidney transplant recipients: a systematic review and meta-analysis. Am J Nephrol 2014; 40:315-324.
56. Postorino M, Marino C, Tripepi G, Zoccali C. Abdominal obesity and all-cause and cardiovascular mortality in end-stage renal disease. J Am Coll Cardiol 2009; 53:1265-1272.
57. Elsayed EF, Tighiouart H, Weiner DE, et al. Waist-to-hip ratio and body mass index as risk factors for cardiovascular events in CKD. Am J Kidney Dis 2008; 52:49-57.
58. Foster MC, Hwang S-J, Larson MG, et al. Overweight, obesity, and the development of stage 3 CKD: the Framingham Heart Study. Am J Kidney Dis 2008; 52:39-48.
59. Kramer H, Shoham D, McClure LA, et al. Association of waist circumference and body mass index with all-cause mortality in CKD: The REGARDS (Reasons for Geographic and Racial Differences in Stroke) Study. Am J Kidney Dis 2011; 58:177-185.
60. Chlebowski RT, Grosvenor M, Lillington L, et al. Dietary intake and counseling, weight maintenance, and the course of HIV infection. J Am Diet Assoc 1995; 95:428-432.
61. Hughes V. The big fat truth. Nature 2013; 497:428-430.
62. Feldman AM, Combes A, Wagner D, et al. The role of tumor necrosis factor in the pathophysiology of heart failure. J Am Coll Cardiol 2000; 35:537-544.
63. Horwich TB, Fonarow GC, Hamilton MA, et al. The relationship between obesity and mortality in patients with heart failure. J Am Coll Cardiol 2001; 38:789-795.
64. Kalantar-Zadeh K, Kopple JD, Humphreys MH, Block G. Comparing outcome predictability of markers of malnutrition-inflammation complex syndrome in haemodialysis patients. Nephrol Dial Transplant 2004; 19:1507-1519.
65. Mohamed-Ali V, Goodrick S, Bulmer K, et al. Production of soluble tumor necrosis factor receptors by human subcutaneous adipose tissue in vivo. Am J Physiol 1999; 277:E971-E975.
66. Hakimi AA, Furberg H, Zabor EC, et al. An epidemiologic and genomic investigation into the obesity paradox in renal cell carcinoma. J Natl Cancer Inst 2013; 105:1862-1870.
67. Lavebratt C, Dungner E, Hoffstedt J. Polymorphism of the AHSG gene is associated with increased adipocyte beta2-adrenoceptor function. J Lipid Res 2005; 46:2278-2281.
68. Li L, Kalantar-Zadeh K. Obesity that makes kidney cancer more likely but helps fight it more strongly. J Natl Cancer Inst 2013; 105:1848-1849.
69. McIntyre CW, Burton JO, Selby NM, et al. Hemodialysis-induced cardiac dysfunction is associated with an acute reduction in global and segmental myocardial blood flow. Clin J Am Soc Nephrol 2008; 3:19-26.
70. Rauchhaus M, Coats AJ, Anker SD. The endotoxin-lipoprotein hypothesis. Lancet 2000; 356:930-933.
71. Jandacek RJ, Anderson N, Liu M, et al. Effects of yo-yo diet, caloric restriction, and olestra on tissue distribution of hexachlorobenzene. Am J Physiol Gastro-intest Liver Physiol 2005; 288:G292-G299.
72. Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med 1999; 341:577-585.
73. Weber MA, Neutel JM, Smith DH. Contrasting clinical properties and exercise responses in obese and lean hypertensive patients. J Am Coll Cardiol 2001; 37:169-174.
74. Kalantar-Zadeh K, Kopple JD. Obesity paradox in patients on maintenance dialysis. Contrib Nephrol 2006; 151:57-69.